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Introduction: Allogenic dendritic cells (DCs) generated from healthy donors, who are complete or partially
HLA-matched, have been used for clinical trials. One of the sources for allogenic DCs is umbilical cord blood
(UCB) cells. However, as far as cord blood cells are concerned, looking at their naïve nature, there is a concern as to
whether the DCs generated from them will have enough potential to elicit a proper T cell response. For this, we
compared CD11c+ UCB-DCs/ Cytotoxic T lymphocytes (CTLs) with the conventional source, i.e. peripheral blood (PBL)
monocyte DCs/CTLs, using various parameters.
Methods: CD11c+ DCs generated from the two sources were compared morphologically, phenotypically and
functionally. Functional assays included antigen uptake, chemotactic migration and MLR (mixed lymphocyte
reaction). The CTLs generated were examined for the activation markers, granzyme A & granzyme B, and IFN-γ
secretion. MUC1 (STAPPVHNV) peptide-specific CTLs were quantified by Streptamer staining. In vitro CTL activity
was assessed by their efficiency in killing MCF-7 cells. For in vivo CTL assay, a xenograft of MCF-7-luc-F5 cells in
female NOD/SCID mice was employed. Regression of tumors in mice was monitored using an in vivo imaging
system before and after ten days of CTL infusion. Statistical analysis of all the experiments between the two
groups was evaluated by one-way ANOVA.
Results: The CD11c+ DCs from the two sources were morphologically and phenotypically similar. Their capacity
to uptake antigen, migration towards CCL-19 and MLR activity were equivalent. UCB-CTLs had significantly higher
levels of activation markers, number of MUC1 specific CTLs, IFN-γ secretion and IL-12p70/IL-10 ratio than that of
PBL-CTLs. Hematoxylin and Eosin-stained tumor sections showed T cell infiltration, which was further confirmed
by immunofluorescence staining. In vivo CTL activity was found to be similar with the two sources.
Conclusions: Our data demonstrate that CD11c+ UCB-DCs/CTLs are as potent as standard CD11c+ PBL-DC/CTLs
and could therefore be used as an allogenic source for therapeutic purposes. The findings of this study could
help in taking us one step closer towards the personalized therapy using DC based cancer vaccines.* Correspondence: lslimaye@nccs.res.in
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Dendritic cells (DCs) are crucial for the induction of both
primary and secondary immune responses, as well as for
eliciting immunological tolerance. Their capacity to effect-
ively cross-present exogenous antigens to T lymphocytes
makes DCs essential for the induction of adaptive immune
responses against malignant cells. This unique attribute of
DCs has offered the possibility of developing clinical pro-
tocols involving DCs for use in cancer immunotherapy.
DCs were introduced as adjuvants in vaccination
strategies that aimed to induce antigen-specific effector
and memory cells. DC therapy represents a new and
promising immunotherapeutic approach for the treat-
ment of advanced cancers. In the last two decades,
large numbers of clinical trials have been conducted
using DC vaccines targeting different kinds of tumors,
and it was found that they were able to initiate promising
clinical responses against a number of diseases, like renal
cell carcinoma, melanoma, HIV, multiple myeloma, acute
myeloid leukemia, breast cancer etc. [1–13]. Immuno-
therapies with allogeneic DCs pulsed with tumor anti-
gens to generate specific T cell responses have been
tested in clinical trials with patients having solid tumors
as well as in different hematological malignancies [14, 15].
Allogeneic DCs can be generated from CD34+ cells de-
rived from umbilical cord blood (UCB) [16–28]. Thus,
UCB could be exploited as an additional source for the
generation of allogeneic DCs. UCB-derived DCs have
been used in the pilot phase of clinical trials as well, in
hematological disorders like AML, as a therapeutic agent
to increase the survival of patients [29, 30].
We have earlier standardized methods for the large
scale generation of DCs from UCB-derived CD34+
cells and mononuclear cells (MNCs), [25, 26] and DCs
with enhanced functionality [31]. These DCs were
characterized by immunophenotyping and functional
assays like mixed lymphocyte reaction (MLR), antigen
uptake and chemotactic migration. However, for effica-
cious DC vaccines, the basic requirement is that the
DCs should generate effector and memory cytotoxic T
lymphocytes (CTLs), to elicit a comprehensive immune
response. The standard treatment procedures utilize
peripheral blood (PBL) monocyte-derived DCs. There
are very few reports where the potency of UCB-derived
DCs has been compared with PBL monocyte-derived
DCs [32, 33]. Therefore, here we report a systematic
study of a comparison between UCB-DCs/CTLs and PBL-
DCs/CTLs, using various parameters. As the basis of CTL
assay is HLA-A*0201-restricted, which is a major histo-
compatibility complex (MHC) class I polymorphism, we
generated DCs from HLA-A*0201positive PBL/UCB sam-
ples. We then carried out in-depth characterization and
functionality tests with these DCs/CTLs. Data generated
from this study clearly demonstrate that UCB-DCs are aspotent as their standard vaccine counterparts i.e., PBL
monocyte DCs, and could therefore be used as an allo-




The recombinant human cytokines used for the study
were fms-like tyrosine kinase-3 ligand (Flt-3L), throm-
bopoietin (TPO), stem cell factor (SCF), IL-4, IL-2, IL-
7, granulocyte-macrophage colony stimulating factor
(GM-CSF), TNF-α, CD40L (CD40 ligand) and macro-
phage inflammatory protein 3β (CCL-19). All recombin-
ant human cytokines were purchased from Peprotech
Asia, Rehovot Israel.
Antibodies
The antibodies used for flow cytometry were mouse anti-
human mAbs: CD1a, CD25, CD11c, CD40, CD8 - antigen
presenting cell (APC)-tagged; CD58, CD54, CD80,
CD83, CD86, HLA-A2, CD45RA, granzyme A -
phycoerythrin (PE)-tagged; CD3, HLA-DR, HLA-ABC,
granzyme B - fluorescein isothiocyanate (FITC)-tagged
and CD 69 PECy7-tagged. For immunofluorescence stain-
ing primary antibody was mouse anti-human purified
CD3 and secondary antibody was goat anti-mouse tagged
with Alexa Fluor® 488 (Life technologies, MA, USA). All
monoclonal antibodies and respective isotype controls
used for the study were purchased from BD pharmingen
(San Diego, CA, USA).
Cell lines
MCF-7 was used in the cell lysate preparation, in vitro and
in vivo CTL assay. MCF-7-luc-F5 (Caliper Life Sciences,
Hopkinton, MA, USA) was used for in vivo CTL assay
using in vivo imaging system (IVIS). H1229 and SH-SY5Y
were used as nonspecific targets for the CTLs generated
from the MCF-7 lysate-pulsed DCs.
Culture medium and other reagents used
Iscove’s modified Dulbecco’s medium (IMDM), Roswell
Park Memorial Institute-1640 (RPMI-1640), (DMEM),
Dulbecco's modified Eagle's medium/nutrient F-12 Ham
1:1 nutrient mixture (DMEM/F-12 media) and IMDM
without phenol red were procured from Sigma Aldrich, St.
Louis, MO, USA. Histopaque (ρ-1.007g/ml), FITC-labeled
dextran (40 kDa), Wright Stain, Giemsa Stain, Hematoxylin
Solution-Mayer’s, Eosin Y solution, DPX mountant, lipo-
polysaccharide (LPS), keyhole limpet hemocyanin (KLH),
dimethyl sulfoxide (DMSO), PPO, POPOP were all from
Sigma Aldrich, St. Louis, MO, USA; ELISA kit (BD OptEIA);
heparin (SRL Pvt. Limited Mumbai, India); Rosette Sep for T
cell isolation (Stem Cell Technologies, Vancouver, Canada);
[3H] thymidine (240 GBq/ milli mole, BRIT, Navi Mumbai,
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(ebiosciences San Diego, CA, USA) Steptramers (Iba-
lifesciences, Goettingen, Germany), Luciferin D Potassium
Salt (Perkinelmer, Waltham, MA, USA), reduced growth
factor Matrigel (Becton-Dickinson), HBSS buffer (Life tech-
nologies, MA, USA) and CRYO-OCT compound (Thermo
Fisher Scientific Inc. MA, USA).
Methods
Ethical statements for use of human samples
Protocols for collection and processing of all human
samples used in this study were approved by the Insti-
tutional Ethics Committee (IEC of NCCS) and Institu-
tional Committee for Stem Cell Research (IC-SCR of
NCCS). The guidelines followed by these committees
are in accordance with the Declaration of Helsinki.
Prior informed written consent was obtained from the
donors. The human samples used in this study were as
follows:
1. Umbilical cord blood: these were used for
generating DCs and for isolating autologous T cells
for CTL assay
2. Peripheral blood: these samples were used to isolate
MNCs and T cells for use in MLR assays
3. Buffy coat: these were used for generating DCs and
for isolating autologous T cells for CTL assay
Collection of blood samples
Collection of blood samples was as follows:
1. Umbilical cord blood (UCB): the samples were
collected in preservative-free heparin (40 IU of
heparin/ ml of blood) with plain IMDM in sterile
containers. Then samples were brought to the
laboratory on ice packs and were processed to
isolate MNCs
2. Peripheral blood (PBL): buffy coat bags were
brought to the laboratory on ice packs and were
subsequently processed to isolate MNCs
Processing of blood samples
Processing of blood samples was as follows:
1. Isolation of MNC from UCB and PBL: UCB MNCs
and PBL MNCs were separated by Histopaque®
density gradient centrifugation. Turk’s solution was
used to take nucleated cell counts, using a
hemocytometer. MNCs thus obtained were used
for DC generation
2. Isolation of T-cells from peripheral blood: T cells
were isolated from blood for MLR assay, using the
RosetteSep™ (negative selection kit), according to the
manufacturer’s instructionsIn vitro generation and culture of DCs from UCB
DCs were generated from umbilical cord blood samples
by our method as described earlier [25, 26, 31]. Briefly,
MNCs from peripheral blood samples were seeded at a
density of 107 cells/2 ml/well in six-well plates. Mono-
cytes were enriched by plastic adherence and were used
for DC generation. The terminal differentiation of pre-
cursor cell populations to DCs were induced by subse-
quently culturing them with GM-CSF (50 ng/ml) and
IL-4 (30 ng/ml) for 3 days and GM-CSF (50 ng/ml) +
TNF-α (50 ng/ml) for 4 days in IMDM supplemented
with 5 % autologous/AB+ plasma. Immature DCs were
harvested on day 5 and were used for antigen uptake
assay. On day 7, the cells were subjected to maturation
with a combination of pro-inflammatory signal, a com-
bination of TNF-α, LPS and CD40L, at the concentra-
tion of 100 ng /ml each, for 48 h. Mature DCs were
used for all other assays. Experimental design for gen-
eration of DCs is given in a flow chart in Additional file
1: Figure S1.
In vitro generation and culture of DCs from PBL
Mononuclear cells were obtained by histopaque density
gradient centrifugation of buffy coat samples. MNCs
were seeded at the density of 107 cells/well in six-well
plates containing 2 ml of IMDM supplemented with 1 %
human AB+ plasma. The cells were kept for 1.5 h at 37 °C
in a 5 % CO2 incubator and the non-adherent and the
loosely adherent cells were removed by washing with
IMDM. The adherent cells were used for DC generation
in a similar way as described for the UCB samples. The
experimental design for generation of DCs is given in a
flow chart in Additional file 1: Figure S1.
Morphological and phenotypic analysis
Morphological characterization of DCs was done by stain-
ing with Wright and Giemsa stains and observing under a
microscope. For phenotypic analysis, the cells were stained
with a panel of ten antibodies namely CD1a, CD11c,
CD40, CD58, CD54, CD80, CD83, CD86, HLA-DR and
HLA-ABC along with appropriate isotype controls and ac-
quired using the FACS Canto II (BD San Jose, CA, USA)
[25, 26, 31].
Flow Cytometry
For all flow cytometry analysis, the cells were suspended
in 100 μL of cold PBS containing 1% BSA. Specific la-
beled mAbs and appropriate isotype controls were added
and the cells were incubated on ice for 30 minutes. Cells
were washed thrice with ice cold PBS and re-suspended
in 1 % paraformaldehyde. Cells were acquired using the
FACS Canto II. Data were analyzed by FACS Diva (BD)
and histogram overlays were prepared using FlowJo
(LLC, Ashland OR, USA).
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The assays used to access the functionality of in vitro gen-
erated UCB-DCs and PBL-DCs were as follows:
1. Endocytosis assay with FITC-tagged dextran: we
tested the receptor-mediated endocytosis in the gen-
erated DCs using FITC-tagged dextran. Immature
DCs were harvested on day 5 and incubated with
FITC-dextran (20 μg/ml), either at +4 °C (internal-
ization control) or at +37 °C, for 30 and 60 minutes.
The cells were then acquired using the FACS Canto
II [25, 26, 31]
2. Chemotaxis: the chemotaxis of the in vitro generated
UCB and PBL-DCs toward CCL-19 was assessed in a
24-well cell culture plate with BD Falcon ™ Cell
culture inserts (pore size 8.0 μm) as described earlier
[25, 26, 31]
3. Mixed lymphocyte reaction (MLR): the
immunostimulatory capacity of in vitro generated
UCB and PBL-DCs was assessed by MLR. Allogenic T
cells were obtained from peripheral blood of healthy
donors and were distributed at 105 cells per well into
round-bottomed 96-well micro plates (NUNC). Cells
were co-cultured in the presence of graded numbers
of irradiated DCs (2,500 rad, Co 60 source, BRIT, Navi
Mumbai, India) in 200 μL of medium containing 10 %
pooled AB+ plasma. Thymidine incorporation was
measured on day 3 followingan 18-h pulse with [3H]
thymidine (1 μCi/well) (BRIT, India) using standard
procedures [25, 26, 31].Generation of CTLs
CTLs were generated from UCB and PBL samples by
our method as described earlier [30]. Briefly HLA-
A*0201-positive UCB MNCs and PBL MNCs were used
to generate DCs. Immature DCs were pulsed with MCF-
7 lysate to a final concentration of 100 μg/ml of protein
along with KLH (50 μg/ml) for 48 h as maturation stim-
uli in the culture medium for cross presentation of
tumor antigen to autologous/allogenic sorted naïve T
cells. For the negative control set of DCs, the maturation
stimuli comprise 100 ng/ml each of LPS, CD40L and
TNF-α, respectively. The autologous/allogenic naïve T
cells were obtained by sorting of CD3-, CD8-, and
CD45RA-positive cells using the FACS ARIA III (BD).
The naïve T cells were co-cultured with MCF-7 lysate-
pulsed DCs that were generated from the autologous/
allogenic UCB or PBL sample. DC-T cell co-culture was
maintained for 3 weeks with the addition of cytokines
IL-2 (0.1 μg/ml) and IL-7 (5 μg/ml) and weekly re-
stimulation with fresh antigen-pulsed DCs to generate
effector cytotoxic killer T cells. Though obtaining HLA-
A*0201-positive cord blood samples was relatively easierfor CTL assay this was not true for peripheral blood
samples. PBL were obtained as buffy coat samples from
blood banks after getting institutional ethical clearance.
Subsequently they were screened for HLA-A*0201 posi-
tivity, and only HLA A2-positive samples could be used
for CTL assay. The frequency of obtaining HLA-A*0201
positivity was 1 in 10 samples screened. Procuring large
volumes of HLA-A*0201-positive PBL samples (to iso-
late naïve T cells) also had ethical constraints. Moreover,
literature suggests that a lower titration of target to
killers have been used by many investigators [34, 35]. So
we had taken into consideration the intermediate titra-
tion ratio of target to killers in this study (i.e., 1:0,
1:3……1:18). The experimental design for generation of
CTLs is given in a flow chart in Additional file 2: Figure
S2.
Functional characterization of CTLs
CTLs were characterized as follows:
1. Assessment of activation by surface markers
expression: on day 5 or day 7 of UCB/PBL, DC-T cell
(DC-TC) co-culture cells were harvested and screened
for the expression of early activation marker like
CD69 along with CD25. After staining with CD69 and
CD25 mAbs or with appropriate isotype controls, cells
were acquired using the FACS Canto II from BD.
2. Intra cytoplasmic staining for granzyme A and B:
CTLs generated in vitro were tested for the
presence of these serine proteases enzymes within
the intracellular compartments. Cells were
harvested on day 21 of UCB/PBL DC-TC co-cultures
and were stimulated by phorbol 12-myristate 13-
acetate (PMA) (40 ng/ml) and ionomycin (100 ng/
ml), along with Golgi stop Brefeldin A (1:1,000
diluted) for 4 h. After harvesting, the cells were
subjected to surface staining with CD8 for 30
minutes. After fixation and permeabilization,
granzyme A and B mAbs and appropriate isotype
controls were added and the cells were incubated
on ice for 60 minutes. Cells were acquired using
the FACS Canto II from BD.
3. Streptamer staining for Mucin1 (MUC1)-
STAPPVHNV-specific T cells: different specificities
of CTLs arise when naïve T cells are cultured with
pulsed DCs, depending on the antigen presentation
capacity of the DCs. The cells were harvested on
day 21 of UCB/PBL DC-TC co-culture. MUC1-
STAPPVHNV [36] tagged with R-PE was used to
estimate the presence of MUC1-specific CTLs as
per the manufacturers’ instructions. After staining,
cells were acquired using the FACS Canto II from
BD. The schematic of the staining procedure is
given in Additional file 3: Figure S3.
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supernatant from the in vitro-generated pulsed
UCB-DCs or PBL-DCs and sorted naïve T cell co-
cultures was collected on day 21 and stored at −20
°C. IL-12p70 and IL-10 or interferon gama (IFN-γ)
content in the supernatants were assayed by ELISA
using BD OptEIA™ ELISA kit (BD, Pharmingen) as
previously reported [31]. The amount of secreted
interleukins present in the samples was calculated
by the standard curve method.
In vitro CTL assay
CTL assays were performed as described previously
[31]. Briefly CTLs generated from unpulsed and pulsed
sets of DCs were co-cultured with the target cells
MCF-7 for 18 h in a flat bottom 96-well plate. Cells
were then washed with plain media and then pulsed
with [3H] thymidine for 8 h. Percent killing of MCF-7
was calculated by P-JAM assay using the formula:
% Killing ¼ CPMA Target alone – Target þ Killer½ 
 100=CPMA Target alone
In vivo CTL assay (xenograft model)
The NOD/LtSZ-scid/scid mice were purchased from
Jackson Laboratories and were bred in the animal facil-
ity of our institute. The study was conducted adhering
to the institution guidelines for animal husbandry and
has been approved by the Institutional animal ethical
committee-NCCS /Committee for the Purpose of Control
and Supervision of Experiments on Animals (IAEC-
NCCS/CPCSEA). Animal procedures involving intraven-
ous (IV) infusion were carried out under anesthesia. The
right flanks of age-matched female NOD/SCID mice, 4–6
weeks old, were subcutaneously injected with 4 × 106 of
MCF-7-luc-F5 cells in a total volume of 200 μL, which in-
cluded 100 μL cell suspension in HBSS buffer plus 100 μL
reduced growth factor Matrigel (Becton-Dickinson). Estra-
diol valerate USP (Cadila Healthcare Ltd.) (200 μg) was
injected intraperitoneally (i.p.) per day from day zero until
the tumor size reached a minimum of around 5 mm in
lengthand in width, i.e., 62.5 mm3 in volume. One week
after stopping estradiol injections, the mice were divided
into three groups namely the control, the UCB-CTL and
the PBL-CTL groups. The first day of imaging was consid-
ered as day zero. Before imaging the mice, tumor volume
measurements were done for each mouse in all groups
using digital Vernier calipers and the volume was calcu-
lated using the formula (length × width × width)/2. Mice
were anesthetized by ketamine and xylazine (4:1 ratio)
0.05 ml per 20 grams of body weight. Then Luciferin D
potassium salt (15 mg/ml) 0.2 ml was administered i.p.
per mouse, followed by imaging using the IVIS 200(Xenogen, PerkinElmer, MA, USA) and analysis by Living
Image® (version 4.4). On the following day, each mouse in
the UCB and PBL test group was infused via the tail vein
with 107 CTLs, generated from pulsed UCB and PBL-
DCs, respectively. No CTLs were infused in the control
sets. On the tenth day post CTL infusion, tumor volume
measurements were taken and documented, followed by
IVIS imaging as described above. On the same day, mice
were sacrificed and the tumors were harvested and di-
vided in two equal halves. One half was fixed in 10 % for-
malin for paraffin sectioning, followed by H&E staining.
Images were taken using the Leica DMI6000 inverted
microscope. The other half of the tissue was embedded in
CRYO-OCT compound and kept frozen at −80 °C till fur-
ther use. Shandon Cryotome was used to obtain 10-μ
cryosections of frozen tissues. Mouse anti-human CD3
primary antibody and goat anti-mouse secondary antibody
conjugated with Alexa Fluor® 488 was used in immuno-
fluorescence staining to confirm the presence of infiltrat-
ing T cells in the xenograft tissue. Nuclei were stained
with 4',6-diamidino-2-phenylindole (DAPI) to demarcate
cellular structures and images were taken using the Zeiss
LSM 510 Meta confocal microscope.
Statistical analysis
Different variables of UCB-DCs/CTLs and PBL-DCs/
CTLs were compared. All results were expressed as
means ± SD. Statistical analysis and graphs were pre-
pared using SigmaPlot software (Version 11) (Jandel
Scientific, CA, USA) and GraphPad Prism 6 Software
(San Diego, CA, USA). All the statistical analysis of ex-
periments comparing the two groups was evaluated by
one-way analysis of variance (ANOVA). Probability
values ≤0.05(*), ≤0.01(**) and ≤0.001(***) were consid-
ered statistically significant.
Results
UCB and PBL-derived DCs have similar morphology and
phenotype
DCs were generated from PBL monocytes and UCB
MNCs as described earlier (a flow chart illustration is
depicted in Additional file 1: Figure S1). The morphology
of CD11c+ DCs from the two sources was studied by
observing the culture plates under a phase contrast micro-
scope (Fig. 1a, b, e, f ) and by observing Wright-Giemsa
stained culture plates (Fig. 1c, d, g, h). They showed
stellate processes with a typical veiled appearance, dense
cytoplasm, irregular nuclei and some cells in clumps,
forming clusters. Wright-Giemsa stained cells showed
long cytoplasmic projections i.e., dendrites, the hallmark
of these cells. The DCs were further identified phenotypic-
ally by staining them with a panel of ten antibodies and
acquiring on a flow cytometer. Representative FACS histo-
gram profiles for UCB and PBL are depicted in Fig. 1i and
Fig. 1 Morphology and phenotype of dendritic cells (DCs) generated from the two sources: Phase contrast images of umbilical cord blood DCs
(UCB-DCs) (a, b) and peripheral blood PBL DCs (PBL-DCs) (e, f) at lower and higher magnification, respectively. Both sources generated the typical
clusters of mature DCs. Wright-Giemsa-stained adherent cell clusters of UCB-DCs (c) and PBL-DCs (g) at lower magnification and morphology of
single cells at higher magnification (d, h). FACS histogram overlay profile of a representative experiment from UCB-DCs (i) and PBL-DCs (j). Black
line isotype control and colored lines specific CD molecules. Percent expression and mean fluorescence intensity (MFI), respectively, from three
samples are shown in (k, l). It is evident that fully mature DCs were generated and there was no significant difference in the expression level of
different surface markers, except for CD40, which was higher in UCB-DCs (k). In terms of MFI, CD58 was found significantly higher in UCB-DCs
and CD54 in PBL-DCs (l). The data shown are mean ± SD, n = 3 (*p <0.05). PE phycoerythrin, FITC fluorescein isothiocyanate
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SD, n = 3) for percent CD expression is shown in Fig. 1k
and MFI values in Fig. 1l. DCs generated from both
sources had higher expression of DC-specific markers
such as CD 1a, 11c, 80, 83, 86, etc. Typical DC-specific
markers along with the co-stimulatory molecules, associ-
ated integrins and adhesion molecules were also expressed
on the cells from both sources and were comparable.
There was no significant difference in the percent expres-
sion of markers on DCs from the two sources, except for
CD40 (Fig.1k), which was higher in UCB-DCs. There was
also a significant difference in the MFI of CD58 (Fig. 1l),
which was higher in UCB-DCs, and CD54 (Fig. 1l), which
was higher in in PBL-DCs (p ≤0.05). These data under-
score the fact that UCB-DCs are equivalent in nature to
PBL DCs with respect to morphology and phenotype.
UCB-DCs and PBL-DCs are functionally equivalent
DCs have the characteristic property of activating naïve T
cells, and this functionality depends upon the efficacy oftheir antigen uptake, chemotactic migration, antigen pro-
cessing and presentation. We tested these functional attri-
butes by performing in vitro assays, such as uptake of
FITC-tagged dextran, chemotactic migration towards
CCL-19, and MLR. We observed that both immature DC
sets performed uptake of dextran-FITC within 30 and 60
minutes of the incubations tested. After 60 minutes of in-
cubation time, there was 51 % uptake in UCB-DCs,
whereas there was 49 % uptake in PBL-DCs. Figure 2a
shows a histogram overlay profile of a representative sam-
ple with MFI values in brackets. Figure 2b shows cumula-
tive data from three samples for percentage uptake of
FITC-tagged dextran and Fig. 2c bar graph shows the cu-
mulative MFI values from three samples (mean ± SD, n =
3). Migratory ability of the DCs towards CCL-19 was stud-
ied by in vitro assay using cell culture inserts as described
earlier. As is evident from Fig. 2d (mean ± SD, n=3), mi-
gration ability was also similar between DCs from both
sources. The MLR assay was performed by co-culturing
DCs and T cells in different ratios and then checking the
Fig. 2 Functional characterization of dendritic cells (DCs). a FACS histogram overlays of dextran-fluorescein isothiocyanate (FITC) uptake profile of
a representative experiment from umbilical cord blood DCs (UCB-DCs) and peripheral blood DCs (PBL-DCs) with mean fluorescence intensity (MFI)
values in brackets, and b data from three experiments for percentage antigen uptake. c Cumulative MFI values from three samples. d Chemotaxis
of DCs towards CCL-19. Low spontaneous migration was observed in the wells, without CCL-19, whereas both UCB-DCs and PBL-DCs efficiently
migrated towards CCL-19 gradient. e Mixed lymphocyte reaction (MLR) from three independent experiments reveals that DCs generated from both
sources exhibited similar MLR at a different effector-to-target ratio. The data shown are mean ± SD, n = 3 (**p <0.01). CPMA count per minute for beta
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dine uptake. Figure 2e (mean ± SD, n = 3), clearly shows
that both types of DCs elicited similar responses. Out of
the six ratios tested, only at one ratio i.e., 1:100, did PBL-
DCs appear to be significantly superior (P = 0.007); P
values for the other ratios tested were 0.752, 0.107, 0.218,
0.775 and 0.258, respectively, which were not significant.
This finding is important because MLR measures earlyevents in the sensitization phase of antigen-specific cell-
mediated immune response. With respect to these three
attributes, we can conclude that UCB-DCs are as robust
in functionality as PBL monocyte-derived DCs.
Characterization of CTLs obtained from UCB and PBL-DCs
CTLs were generated by co-culturing sorted naïve







Fig. 3 Functional characterization of CTLs: (a) Dot plot depicting the gating strategy and expression of activation markers CD69 & CD25 for a
representative experiment from UCB/PBL. The dual positive cells from pulsed UCB/PBL-DCs are seen in upper right quadrant of lower panel. (b)
Showing significantly higher CD69 & CD25 dual positive cells in UCB-derived CTLs than that of PBL-derived CTLs. (c) The gating strategy for
intracellular staining of granzyme A & B in CTLs. Upper right quadrant in lower panel shows dual positive cells. (d) Showing presence of dual
positive cells for granzyme A & B in pulsed UCB/PBL derived CTLs. (e) Dot plot and histogram showing the presence of MUC1 STAPPVHNV-
specific T cells (lower panel) in total pool of CTLs from both the sources. (f) Showing significantly higher percentage of MUC1 specific TCRs in
pulsed PBL/UCB-CTLs set as compared to unpulsed set. MUC1 specific TCRs in pulsed UCB-CTLs set was significantly higher than the PBL
counterpart. (g) UCB-CTLs were capable of secreting significantly higher levels of IFN-γ than that of PBL-CTLs (n=5) in the co-culture derived from
pulsed UCB/PBL-DCs. (h) Represents the levels of IL-10 and IL-12p70 in the co-culture. The UCB-DCs secreted significantly higher level of IL-12p70
and a significantly lower level of IL-10 than PBL-DCs. (I) IL-12 p70/IL-10 ratio in the co-culture. Ratio was significantly higher in cultures with
UCB-DCs as compared to PBL DCs. The data shown are mean ± SD, n = 3/5 (*p < 0.05, **p < 0.01, ***p < 0.001)
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illustration is depicted in Additional file 3: Figure S3).
CTLs thus generated by pulsed DCs from both sourceswere characterized for activation of surface markers such
as CD69 and CD25, and intracellular levels of granzyme A
and granzyme B. MUC1-specific CTLs were quantified by
Kumar et al. Stem Cell Research & Therapy  (2015) 6:184 Page 9 of 15staining with MUC1-specific streptamer. Levels of se-
creted IFN-γ, IL-12p70 and IL-10 in the DCs and T cells
co-cultured supernatant were assessed by ELISA.
The expression of activation markers is significantly higher
in UCB-derived CTLs
Activation of T lymphocytes, both in vivo and
in vitro, induces the expression of CD69. Induction
of CD25 (the high affinity IL-2 receptor) and CD69
(the early activation antigen) is a characteristic fea-
ture of activated CTLs. Activation markers were de-
tected on the cell surface using flow cytometry. Our
data clearly show that CTLs generated from both
sources express these two molecules. The FACS pro-
file of one representative sample is shown in Fig. 3a.
Figure 3b shows cumulative data from five samples
(mean ± SD, n = 5). The data show that the CTLs
from UCB-DCs appeared significantly more potent
(P = 0.008) than their PBL counterparts in expres-
sion of these activation-associated markers.
Percentage of granzyme-positive cells is also higher in
UCB-CTLs
A major pathway by which the CTLs induce their
killing activity is via targeted exocytosis of cytoplas-
mic granules containing serine proteases, such as
granzymes. Other locations where the granzymes can
be detected are rough endoplasmic reticulum, golgi
complex, and the trans-golgi reticulum, hence intra-
cytoplasmic staining is needed to detect the presence
of these proteases in the cells along with the use of
Golgi stop (Brefeldin A). We found that the MCF-7
lysate-pulsed PBL-DC-CTLs/UCB-DC-CTLs pro-
duced granzyme A and B. The FACS profile is
depicted in Fig. 3c. Cumulative data from three sam-
ples (mean ± SD, n = 3), showed a higher amount of
these proteases in pulsed UCB-CTLs than in pulsed
PBL-CTLs (Fig. 3d).
UCB-CTLs contain higher number of MUC1-specific CTLs
Out of all of the T cells in a given population, only a
few may be specific for a given peptide against which
its TCR match and are expanded on antigen presenta-
tion along with co-stimulation by APCs. To test the
capability of MCF-7 lysate-pulsed UCB- and PBL-
derived DCs to generate antigen-specific T cells after a
secondary stimulation, sorted naïve HLA-A*0201-posi-
tive CD8+ T cells were weekly re-stimulated with
freshly MCF-7 lysate pulsed HLA-A*0201-positive DCs.
MUC1 is overexpressed in MCF-7 cells and it is also
HLA-A*0201-restricted. The presence of MUC1-specific
CD8+ T cells were quantitated by peptide-specific strep-
tamer. Percentage of MUC1 peptide-STAPPVHNV-
specific TCR present in the proliferating clones of Tcells is represented in Fig. 3e and f, and in schematics
in Additional file 3: Figure S3. We found a significantly
higher percentage of streptamer-positive UCB-CTLs
compared to PBL-CTLs. Figure 3e shows the FACS
profile of one representative sample and Fig. 3f depicts
cumulative data from three samples (mean ± SD, n =
3). These findings suggest that pulsed UCB-DCs and
PBL-DCs were efficient in generating MUC1-specific
CTLs.
UCB-CTLs secrete higher levels of IFN-γ
IFN-γ regulates multiple aspects of CD8+ T cell homeo-
stasis as it promotes CD8+ T cell expansion and memory
cells formation. CTLs are characterized by the secretion
of IFN-γ. DCs from both sources were able to generate
CTLs, which were capable of secreting a substantial
amount of IFN-γ. However, pulsed UCB-CTLs were cap-
able of secreting significantly larger amounts of IFN-γ,
as compared to pulsed PBL-CTLs. Figure 3g represents
cumulative data from five samples (mean ± SD, n = 5).
It is evident from these data that UCB-CTLs are better
than the PBL-CTLs in this respect.
Ratio of IL-12p70 to IL-10 was higher in supernatants of
UCB-derived DC-T cell co-cultures
IL-12 is essential for ontogenesis of effector functions in
T cells and in the establishment of functional memory.
In vitro generated pulsed DCs were able to secrete
higher levels of IL-12p70, as compared to IL-10. The
UCB-DCs showed a better IL-12p70 secretion profile
than PBL-DCs. Figure 3h represents the levels of IL-10
and IL-12p70 in the co-culture. The levels of IL-12p70
(pg/ml) were 64.41 ±4.31 and 41.84 ±1.73 for UCB and
PBL-DCs, respectively. On the other hand, the level of
IL-10 secretion by PBL-DCs was higher than for UCB-
DCs. The levels of IL-10 (pg/ml) were 49.86 ± 9.72 and
83.53 ± 8.72 for UCB and PBL-DCs, respectively. Figure 3i
represents the ratio of IL-12p70/IL-10. This ratio was
significantly higher in UCB-DCs (mean ± SD, n = 5). It is
evident from these data that the UCB-DCs have a more
favorable T helper (Th)1 cytokine profile, as compared to
PBL-DCs.
The activated CD8+ T cells from both the DCs sources show
comparable CTL activity
In vitro CTL assay
Figure 4a represents the cumulative data from three
different biological replicates at different target-to-T-
cell ratios. All the intermediate titration ratios of
target-to-killers used in this study have shown that
the DCs from the two sources have a similar killing
effect. There was no spontaneous death as is evident
for the 1:0 ratio where we saw zero percent killing as
calculated by the formula in the P-JAM assay. This is
Fig. 4 In vitro cytotoxic T lymphocyte (CTL) assay. a CTL assay data from three experiments depicting the killing efficacy of the target MCF-7 cells
by CTLs generated by pulsed umbilical cord blood (UCB)/periperal blood (PBL)-dendritic cells (DCs). b Percent killing in the irrelevant target cell
line H1229. Negligible killing effect was seen in these sets by pulsed UCB/PBL-DCs. Data shown are mean ± SD, n = 3
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difference was observed in the killing efficiency of
CTLs derived from the two sources. As a negative
control, CTLs were raised with un-pulsed UCB and
PBL-DC sets. The CTLs thus generated were not ef-
fective in killing the target cells. To check the target
specificity, CTLs obtained from MCF-7 lysate-pulsed
UCB DCs were used in the CTL assay against H1299
and SH-SY5Y cell lines; a negligible killing effect was
seen in these sets. Figure 4b shows the percent killing
of the irrelevant target cell line H1229. The CPMA
value in the SH-SY5Y control was 1,710 (SD ± 30),
and in the pulsed and un-pulsed group at highest
target-to-T-cell ratios were 1680 (SD ± 47) and 1,650
(SD ± 36), respectively. Additional file 4: Figure S4A
and B depict the propinquity interaction of pulsed
DCs and naïve T cells in the co-culture system. It is
clearly seen (Additional file 4: Figure S4C) that CTLs
from un-pulsed DCs do not cling to the target MCF-
7 cells in the CTL assay. Additional file 4: Figure
S4D and Additional file 4: Figure S4E illustrate the
assailing nature of CTLs from pulsed DCs towards
the target cells.
In vivo CTL assay-xenograft model
To assess the in vivo potency of the CTLs generated from
both the sources, a xenograft model was used. Representa-
tive IVIS images of one experiment including control (not
infused with CTLs), UCB and PBL groups on day 0 and
day 10 are depicted in Fig. 5a and b, c and d, and e and f,
respectively. There was marginal change in tumors in the
control group, whereas in both the treated groups there
was a significant decrease in the radiance. Three inde-
pendent experiments having two or three mice in the con-
trol group and five mice in each test group were
performed using 37 female NOD/SCID mice, 7 in the
control set and 15 mice each in the UCB and PBL sets.Figure 5g represents cumulative data for average radiance
(p/sec/cm2/sr) of three experiments. There was a signifi-
cant regression in the tumor mass in the UCB group and
PBL group on day 10 as compared to day 0, after CTL in-
fusion. Figure 5h depicts the cumulative data for tumor
volume (mm3) from three experiments, which shows that
there was a significant decrease in tumor volume in the
UCB group and the PBL group in the experimental time
window, as compared to the control group. H&E staining
for the MCF-7-luc-F5 xenograft tumor section for the
control set is depicted in Fig. 5i and j. Figure 5k and l, and
Fig. 5m and n represent UCB and PBL-CTLs infused test
samples, respectively. CTL infiltrations were clearly evi-
dent (indicated by arrows). Figure 5o-q shows the im-
munofluorescence staining data for one slice of the
section, which further confirms the T cell infiltration
inside the tumor. Figure 5r bar graph shows the quantifi-
cation of tumor-infiltrating T cells, which was enumerated
by Z stack using the Zeiss LSM 510 Meta confocal
microscope.
Discussion
DC-based vaccination is an attractive immunotherapeu-
tic strategy, because of its ability to induce tumor-
specific T cell responses, which offers the desired anti-
tumor effects with minimal toxicity. Allogenic DCs gen-
erated from healthy donors (HLA matching or partially
matching) have been used in clinical trials as DC vac-
cines. These DCs initiated a CTL response and induced
regression of the tumor [1]. Allogeneic DCs can also be
generated from CD34+ cells derived from UCB. Our
earlier studies had shown that UCB can serve as an
alternative source for generating a homogenous DC
population with high cell numbers [25, 26, 31]. However,
as UCB are naïve cells, there is concern as to whether the
DCs generated from them would elicit a CTL response as
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Fig. 5 In vivo cytotoxic T lymphocyte (CTL) assay xenograft model. Representative image from one of the experiments showing average
radiance (measured on the in vivo imaging system (IVIS)) from female NOD/SCID mice bearing tumor consisting of MCF-7-luc-F5 cells. a, b Average
radiance from a control mouse on day 0 and day 10. c and d, e and f Average radiance from the umbilical cord blood (UCB)/peripheral blood (PBL)-
CTLs group of mice on day 0 and day 10 post CTLs infusion. g Average radiance data of three experiments on day 0 and day 10 post CTLs infusion.
There was significant regression in the tumor in both treatment groups infused with pulsed UCB/PBL-CTLs. Horizontal lines mean values ± SD. h Tumor
volume on day 0 and day 10 post CTLs infusion. Similar significant reduction in the tumor mass was observed in both treatment groups infused with
pulsed UCB/PBL-CTLs. i, j H&E-stained section of MCF-7-luc-F5 cell xenograft tumor from a control mouse showing no infiltrating T cells. k and l, m
and n H&E-stained sections from a mouse infused with pulsed UCB/PBL-CTLs. Infiltrating CTLs in both treatment groups are observed (arrows).
o-q Immunofluorescence images of sections stained with anti-human CD3 Ab, which further confirms the absence and presence of CTLs in
the control and treatment group infused with pulsed UCB/PBL-CTLs, respectively. r Quantification of tumor-infiltrating T cells, which was enumerated
by Z stack using the Zeiss confocal microscope. Data shown are mean ± SD, n = 3 (*P <0.05, ** P <0.01, *** P <0.001)
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To gain a better insight into this, we performed a system-
atic comparative study of standard PBL monocyte-derived
DCs and UCB-generated DCs, with emphasis on CTL
characterization and in vitro and in vivo CTL assays.
DCs generated from the two sources were similar in
morphology and phenotype. Starting with 107 MNCs per
sample, 3.11 ± 1.495 × 107 DCs were generated from
three UCB samples and 0.53 ± 2.771 × 107 DCs were
generated from three PBL samples. Their functional
attributes, such as antigen uptake capacity and ability to
migrate towards a chemokine gradient of CCL-19 and
MLR activity, i.e., potent immunostimulatory capacity,
were equivalent. The CTLs generated were examined for
activation markers (CD69 and CD25), granzyme A and B
and quantitation of MUC1 peptide (STAPPVHNV)-spe-
cific CTLs by streptamer. Expression of granzyme A and
B in human cytotoxic lymphocyte subsets as analyzed by
flow cytometry have been reported by Grossman et al.
[37]. The cytokines secreted by UCB-DCs and PBL-
DCs in the co-culture system were favorable for a
Th1 response. A low level of interleukins in the long
term cultures is in accordance with the findings of
Wong KL et al. [38]. Our data indicate that CTLs
from UCB-DCs are superior to CTLs from PBL-DCs.
Cytotoxic T lymphocytes are important constituents
of an adaptive immune system. We tested the level of
the known HLA-A*0201-restricted MCF-7-associated
antigen, MUC1- STAPPVHNV peptide, by the strep-
tamer assay and found that the pool of CTLs had a
high percentage of MUC1-specific CTLs. As UCB T
cells have different activation thresholds as compared to
T cells in adults, it appears that the combination of UCB-
DCs with UCB T cells generated superior levels of MUC1-
specific CTL than that of PBL-DCs. However cross-
stimulation of UCB-DCs with adult T cells, and vice-versa,
would be required to ascertain if the increased potency
was due to the presenting and/or responding cell type.
Thus, a pure antigen-specific CD8+ T cell population
could be generated, which could eventually be sorted out
to give a single antigen-specific response in CTL assays.
Our data are in agreement with those of Fernandez et al.[39] who described an in vitro system for the generation
of functional, antigen-specific T cells from human stem
cells, which could eventually provide a readily available
cell source for adoptive transfer immunotherapies, and
also enable better understanding of human T cell
development.
Defense against virally-infected and malignant cells de-
pends on the action of cytotoxic T lymphocytes and nat-
ural killer cells. Although these use several mechanisms to
eliminate target cells, the principal event is secretion of
cytotoxic granules. These granules contain the pore-
forming protein perforin, together with a variety of
granule-associated proteases, which include the gran-
zymes. Target cell recognition by cytotoxic lymphocytes
induces secretion of the cytotoxic granular content to-
wards the target and the induction of death [40]. We saw
high levels of granzyme A and B in UCB-DC CTLs, fur-
ther highlighting their potential killing ability. The in vitro
CTL activity was assessed by determining CTL killing effi-
ciency with MCF-7 as target cells, and we found that
CTLs from both sources exhibited equivalent killing effi-
ciency. All the intermediate titration ratios of target-to-
killers used in this study have shown that the DCs from
the two sources have a similar killing effect. It appears that
a higher titration ratio may also lead us to the same con-
clusions; however, we need to examine this aspect. Never-
theless, we feel that using a higher effector-target ratio
may not change the scenario further in terms of interpret-
ation of the current data. We also found evidence of cyto-
toxic activity specific to tumor antigens in the in vitro
CTL assay, and not against nonspecific targets like H1229
and SH-SY5Y. These data clearly suggest that UCB-DCs/
CTLs are as potent as PBL-DCs/CTLs. In contrast, they
showed ameliorating features. Chang et al. [32] have
also compared PBL-DCs with UCB-DCs using in vitro
assays and they report similar findings. Signaling path-
ways play a decisive role in the differentiation, survival,
expression of co-stimulatory molecules and antigen
presentation capacity of DCs. They have shown that
CBSC-derived DCs have quicker and greater extracellu-
lar signal-regulated kinase (ERK) and Akt phosphoryl-
ation, and weaker p38 phosphorylation, than peripheral
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stimulated with LPS. In our study we have placed em-
phasis on the characterization of CTLs obtained from
DCs of UCB /PBL and also focused on in vivo CTL assays
using a xenograft in NOD/SCID mice.
Cord blood has many advantages over other sources,
such as ready availability, low risk of severe Graft-versus-
host disease and presence of stem cells with high prolifer-
ative potential. Thus, although UCB-DCs had greater cap-
ability in terms of vaccination and activation, there is a
possibility of adverse effects associated with this line of
therapy. These will have to be evaluated in pilot phases of
clinical trials, thereby providing a better assessment and
insight before moving forward with the other phases of
clinical trials. Importantly, to compare the cancer vaccin-
ation or the stability of the two DCs from different re-
sources, one must establish a competitive assay including
UCB-DCs and PBL-DCs, employing immunosufficient
mice. This experiment may yield valuable insight for our
current understanding of effector functions in in vivo set-
tings, which may help to verify the vaccination efficacy for
the two DC sources. In other words, the future of UCB-
derived DC vaccination depends largely on its in vivo be-
havior in patients, for which more stringent experiments
on appropriate animal models need to be executed. Cord
blood stem cells have longer telomeres and have longer
survival. Monocytes from PBL are terminally differenti-
ated cells, and therefore cannot proliferate. The major
disadvantage of cord blood is the low number of stem cells
but this is taken care of by the expansion step in our
method. Cord blood banks from all over the world can be
utilized for this purpose. When a stored sample is revived
for transplantation, a small aliquot can be removed to
generate DCs, which could then be transplanted into
the patient, where they would migrate to lymph nodes
and could elicit a strong T cell response against any re-
sidual tumor cells. de Haar et al. have already started
such pre-clinical trials in the therapy of pediatric Acute
myeloid leukemia using UCB-DCs [29]. Hutten et al.
describe the first pre-clinical evidence for the suitability
of UCB-DC either for the induction or for the reactiva-
tion of minor histocompatibility antigen (MiHA) HA-
1-specific cytotoxic T cells. Their findings are of clinical
significance in transplanted patients suffering from
hematological malignancies [30].
To the best of our knowledge, we provide here for the
first time, direct evidence in a xenograft model of a solid
tumor, an adoptive T cell therapy by using ex vivo ex-
panded CTLs having the antitumor activity derived from
HLA-A*0201-positive UCB and PBL samples. We found
that UCB/CTLs and PBL/CTLs had immunotherapeutic
effects against MCF-7-luc-F5 solid tumors in female
NOD/SCID mice. It is evident from the IVIS data that
there is a significant remission in tumors 10 days afterCTL infusion. The H&E and immunofluorescence stain-
ing of tumor sections revealed substantial homing and in-
filtration of CD8+ T cells. It needs to be determined
whether frequent booster doses of CTLs over longer
period could achieve complete regression. It is also im-
portant to generate DCs by our method from other
sources such as CD34+ from mobilized PBL or enriched
apheresis samples and test their killing efficacy, using a
different cell line in in vivo xenograft experimental
models. We have come a long way since the first clinical
trial with autologous pulsed DCs to stimulate anti-tumor
immunity in humans. We are still in the quest to find the
answer to the main problem i.e., what is required to evoke
a therapeutic immunity against cancer, which emerges by
evading the defense system of the host. With the advance-
ment in technology our perspective on the role of DCs as
adjuvant in cancer immunotherapy has broadened re-
markably. We are at the point of entering a new era, in
which immunotherapy is going to revolutionize the treat-
ment of almost every kind of cancer.
Conclusions
Our data conclusively show that UCB-derived DCs are
equally potent as the standard source of DC vaccines,
i.e., PBL monocyte-derived DCs. In other words, UCB-
DCs or the CTLs derived from them could be used ef-
fectively in allogeneic anti-tumor vaccines for immuno-
therapy, as an alternative to peripheral blood or bone
marrow-derived DCs/CTLs.
Additional files
Additional file 1: Figure S1. Flow chart depicting experiment design
for generation of dendritic cells (DCs). UCB umbilical cord blood, MNC
mononuclear cells, GM-CSF granulocyte-macrophage colony stimulating
factor, PBL peripheral blood, LPS lipopolysaccharide. (TIFF 2506 kb)
Additional file 2: Figure S2. Flow chart depicting experiment design
for generation of cytotoxic T lymphocytes (CTL). UCB umbilical cord
blood, PBL peripheral blood, LPS lipopolysaccharide, DC dendritic cells.
(TIFF 3354 kb)
Additional file 3: Figure S3. Schematics for Streptamer staining. CTLs
cytotoxic T lymphocytes. (TIFF 2289 kb)
Additional file 4: Figure S4. Depicts the interaction of pulsed dendritic
cells (DCs) and naïve T cells. A Clonal expansion of naïve T cells during co-
culture with pulsed DCs. B Larger magnification to show the tethering of
many naïve T cells with a mature DC. C Negligible interaction of unpulsed
cytotoxic T lymphocytes (CTLs) with the target MCF-7 cells. D, E Flocking of
CTLs derived from pulsed peripheral blood (PBL)/umbilical cord blood (UCB)
DCs to the target MCF-7 cells. (TIFF 2950 kb)
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